Baxter spin-off Baxalta has set up UK headquarters in Staines-upon-Thames, with plans to house around 100 employees.

The $6-billion global biotech was launched on July 1 after separating from Baxter, in a move designed to accelerate innovation and optimise R&D productivity.

Baxalta, which has a strong foothold in the haematology and immunology arenas, is planning to launch 20 new products across the globe by 2020.

Commenting on its new HQ, Nicole Farmer, Managing Director of Baxalta UK, said the firm will work with “all stakeholders - patients, healthcare professionals and policymakers - to ensure access and improve standards of care to medicines for patients” across the country.